FDA Approves Nivolumab with Ipilimumab for Unresectable or Metastatic MSI-H or dMMR Colorectal Cancer By Ogkologos - May 9, 2025 578 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the CHECKMATE-8HW study Source RELATED ARTICLESMORE FROM AUTHOR Giredestrant plus everolimus prolongs PFS among patients with ER-positive, HER2-negative, ESR1-mutated advanced breast cancer after the receipt of a CDK4/6 inhibitor EMA Recommends Granting a Marketing Authorisation for Ensartinib Taking on the RAS Challenge MOST POPULAR Can Age Affect Response to Immune Checkpoint Inhibitors? July 6, 2018 No Survival Benefit for Adding Adjuvant Chemotherapy to Endocrine Therapy in... June 15, 2022 Neoadjuvant Pembrolizumab Associated with Limited Side Effects and High Clinical Activity... January 16, 2023 Mobile Care Center Brings Breast Cancer Treatment to Amish and Mennonite... December 18, 2019 Load more HOT NEWS Multiple mRNA Vaccines Show Promise for Treating HPV-Related Cancers Promising Cancer Drug Combines Chemo And Light Therapy Into One Powerful... Treatment for Children with Leukemia Also Effective for Adolescents, Young Adults No Survival Benefit from Adding Adjuvant Chemotherapy to Endocrine Therapy in...
